Corbus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat life threatening (“orphan”) inflammatory-fibrotic diseases with clear unmet needs. Our lead product Resunab™ is a first- in-class oral anti-inflammatory expected to commence Phase-2a clinical trials for the treatment of cystic fibrosis and scleroderma pending FDA […]![]()
